-398_1b7d. pdf) was unanimous, unusual for an ideologically divided court known for split
decisions on blockbuster cases. The same justices upheld President Barack Obama's …

Association for Molecular Pathology v. Myriad Genetics, Inc. says that patents on naturally
occurring genes including BRCA1 and BRCA2 are invalid because DNA segments are …

US physicians, scientists, and patients challenging the validity of commercial patents on
human genes are moving closer to a possible hearing in the US Supreme Court, which they …

In June 2013, the Supreme Court unanimously decided Assn. for Molecular Pathology v.
Myriad Genetics Inc., ruling that isolated naturally occurring sequences of genomic DNA …

The patent community has largely overlooked the intersection of patents and patient rights.
In particular, there is confusion over how the Patent and Trademark Office's (PTO's) issuance …

Can genes be patented? This spring, the Supreme Court will hear a case that may well
decide the question, and the consequences for American biomedicine could be huge. 1 …

Within hours of a Supreme Court decision in June 2013 that seemed to clear the way for
wider testing of the BRCA1 and BRCA2 genes, 2 companies jumped into a lucrative market …

In a major decision issued on June 13, the US Supreme Court unanimously struck down the
patents held by a biotechnology firm on the DNA comprising BRCA1 and BRCA2. 1 These …

Abstract On June 13, 2013, the Supreme Court issued a unanimous decision in Association
for Molecular Pathology v. Myriad Genetics, holding that a naturally occurring DNA segment …

Myriad Genetics, Inc.(Myriad), a young genetics company, specializes in linking human
genes to diseases and establishing the likelihood of a person expressing2 a gene …